Navigation Links
Marshall Edwards Announces Publication of Pre-Clinical Studies in Pancreatic Cancer
Date:6/27/2011

ents, which are based on management's current expectations and are subject to a number of risks and uncertainties, including, but not limited to, our failure to successfully commercialize our product candidates; costs and delays in the development and/or FDA approval, or the failure to obtain such approval, of our product candidates; uncertainties or differences in interpretation in clinical trial results; our inability to maintain or enter into, and the risks resulting from our dependence upon, collaboration or contractual arrangements necessary for the development, manufacture, commercialization, marketing, sales and distribution of any products; competitive factors; our inability to protect our patents or proprietary rights and obtain necessary rights to third party patents and intellectual property to operate our business; our inability to operate our business without infringing the patents and proprietary rights of others; general economic conditions; the failure of any products to gain market acceptance; our inability to obtain any additional required financing; technological changes; government regulation; changes in industry practice; and one-time events. We do not intend to update any of these factors or to publicly announce the results of any revisions to these forward-looking statements.


'/>"/>
SOURCE Marshall Edwards, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Marshall Edwards Announces Closing of Asset Purchase Agreement With Novogen
2. Marshall Edwards Announces Private Placement
3. Marshall Edwards Announces Publication of Phase II Clinical Trial Results Highlighting Activity of Intravenous Phenoxodiol
4. Marshall Edwards Receives Positive Response From NASDAQ
5. Marshall Edwards to Host Annual Meeting of Stockholders
6. Marshall Edwards Receives NASDAQ Notice Of Non-Compliance; Intends To Request Hearing
7. Marshall Edwards Announces Presentation of New Data Showing Activity in Chemotherapy-Resistant Ovarian Cancer Cells
8. Edwards Lifesciences Announces First Implants in U.S. Study of Minimally-Invasive Pulmonic Valve
9. Edwards Resilient Trial Demonstrates Statistically Superior Results for Treating Peripheral Arterial Disease in the Leg
10. Cardium Announces Plans to Acquire Transdel Pharmaceuticals Phase 3 Topical Analgesic and Cosmeceutical Business Assets
11. Curaxis Pharmaceutical Corporation Announces Key Changes to Its Board of Directors and Management Team in Progression Toward Clinical Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... ANGELES , SINGAPORE, and TOKYO , ... announced that it has appointed Roger Crystal , ... most recently served in the Global Business Development Product ... "Roger,s experience in developing business strategy and ... valuable as we continue to partner with biotechnology and ...
(Date:7/28/2014)... NEW PROVIDENCE, N.J. , July 28, 2014 /PRNewswire/ ... meet with Linde,s Healthcare division experts at the ... at McCormick Place in Chicago, Illinois ... nothing less than complete confidence in a reliable medical ... Segment manager. "Linde understands the importance of this critical ...
(Date:7/28/2014)... HILDEN , Germany ... 2014 , ... Begleitdiagnostikums, das auf Basis genomischer Daten aus Plasmaproben ... mit nicht-kleinzelligem Lungenkrebs eingesetzt werden kann  ... zugelassenem  therascreen   EGFR Kit und soll auf Rotor-Gene ...
Breaking Medicine Technology:ImaginAb Appoints Roger Crystal, MD as Vice President of Business Development 2Linde's Healthcare division to display new Hospital Services platform at the national ASHE Conference in Chicago 2QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 2QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 3QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 4QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 5QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 6QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 7
... 17, 2011 Stryker Corporation,s Orthopaedics Division and ... announced an agreement in which OrthoSensor will provide ... Stryker,s Triathlon Knee System. The OrthoSensor Knee Trial ... feedback to surgeons to optimize joint balance during ...
... 2011  ConvaTec, a world-leading developer and marketer of ... announced the appointments of Charles Cerminara and James Moran ... been appointed Vice President and General Manager, Greater China, ... the growth of the Chinese market and to leverage ...
Cached Medicine Technology:Stryker Orthopaedics Enters into Agreement with OrthoSensor for Intelligent Surgical Platform 2Stryker Orthopaedics Enters into Agreement with OrthoSensor for Intelligent Surgical Platform 3ConvaTec Announces Asia-Pacific Leadership Appointments 2
(Date:7/28/2014)... HealthDay Reporter MONDAY, July 28, 2014 (HealthDay ... are more likely to get a pacemaker than people without ... of more than 16,000 people found that those with dementia ... pacemaker than those without the memory-robbing condition. What ... are so much more likely to be treated with a ...
(Date:7/28/2014)... Michigan (PRWEB) July 28, 2014 The ... Drs. Harris, Birkhill, Wang, Songe and Associates, PC that ... and countless tomorrows to come. , The HBWS ... responsible for more than $2.5 million in donations. Through ... title sponsors for the Oakwood Women’s Healthcare Classic for ...
(Date:7/28/2014)... HealthDay Reporter MONDAY, July 28, 2014 ... apnea in children, but a new study confirms that the ... already overweight. The researchers said that,s a concern, because ... problems -- including, ironically, sleep apnea. But they,re not advising ... said, doctors and parents should be aware that a healthy ...
(Date:7/28/2014)... 28, 2014 Lourdes Health System has ... and reduced wait times for veterans needing medical care. ... in the state—and the only one in Camden, Burlington ... Community Care program (PC3). PC3 gives veterans access to ... cannot provide services due to lack of available specialists, ...
(Date:7/28/2014)... 28, 2014 The American ... of professionals engaged in the field of organ ... Transplantation and Immunology Research Network (TIRN), a ... research. As modern organ transplantation continues to diversify, ... could provide more opportunities for physicians, scientists and ...
Breaking Medicine News(10 mins):Health News:Pacemakers Common for Those With Dementia and Irregular Heartbeats 2Health News:Pacemakers Common for Those With Dementia and Irregular Heartbeats 3Health News:Tonsillectomy for Sleep Apnea May Trigger Weight Gain 2Health News:Tonsillectomy for Sleep Apnea May Trigger Weight Gain 3Health News:Lourdes Expands Military Partnership with Veterans 2Health News:Lourdes Expands Military Partnership with Veterans 3Health News:American Society of Transplantation (AST) Launches Transplantation and Immunology Research Network (TIRN); Aims to Expand Research Collaboration & Funding 2Health News:American Society of Transplantation (AST) Launches Transplantation and Immunology Research Network (TIRN); Aims to Expand Research Collaboration & Funding 3
... Neb., March 1 Nelnet, Inc. (NYSE: ... of its 2008 year-end results,as the company,s independent external ... derivative portfolio, which is excluded from base,net income. The ... market open on March 2, 2009. Depending on the ...
... the security alarms of the immune system. After sensing ... alarm to white blood cells or tell them to ... , Researchers at the Emory Vaccine Center and Yerkes ... can respond to the same compound, through two different ...
... office in Tokyo. , ... (PRWEB) March 1, 2009 ... services firm, which provides clinical research support services to pharmaceutical, biotechnology, ... Tokyo, Japan., , ,To meet the growing needs and serve its ...
... Ill. A study in the March 1 issue of ... intrinsic sleep problem specific to attention-deficit/hyperactivity disorder (ADHD) and supports ... deprived and have abnormal REM sleep. , Results ... that is significantly shorter than that of controls. Children ...
... Brian Schweitzer (Chair of the Democratic Governors Association) and ... today applauded President Obama,s reported selection of former DGA ... Human Services. "Our health care system is broken, and ... the effort to fix it," Governor Schweitzer said. "In ...
... for rare, orphan and neglected diseases, launches iWish, which allows people ... these diseases through and image. In addition, people are invited to ... creative solutions for a rare disease or for the community in ... ...
Cached Medicine News:Health News:Vitamin A signals offer clues to treating autoimmunity 2Health News:Underlying sleep problem linked to attention-deficit/hyperactivity disorder in children 2Health News:CheckOrphan Launches iWish to Commemorate Rare Disease Day 2Health News:CheckOrphan Launches iWish to Commemorate Rare Disease Day 3
This 10 L tip was designed for the Pipetman P-2 and P-10. Its MicroPoint design and 2 ul reference mark make it ideal for low volume pipetting....
... to optimize the accuracy and precision of ... is widely recognized by customers throughout the ... over the years and now covers a ... including filter tips, certified pure tips, stepper ...
Designed to fit the Brinkmann Tranferpette and Treff Multi-Channel 300 L Pipettors, this tip provides extra space for repeat pipetting....
The larger volume alternative to the ART Gel 20P, this gel loading tip can load up to 100 L....
Medicine Products: